|
|
|
Volumn 6, Issue 2, 2008, Pages 71-72
|
|
Evidence-based prevention of CINV: What's new in ASCO guidelines?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
ANTIEMETIC AGENT;
ANTINEOPLASTIC AGENT;
APREPITANT;
BORTEZOMIB;
CARBOPLATIN;
CARMUSTINE;
CETUXIMAB;
CHLORMETHINE;
CISPLATIN;
CYCLOPHOSPHAMIDE;
CYTARABINE;
DACARBAZINE;
DAUNORUBICIN;
DEXAMETHASONE;
DOLASETRON MESILATE;
DOXORUBICIN;
EPIRUBICIN;
GRANISETRON;
IDARUBICIN;
IFOSFAMIDE;
IRINOTECAN;
METOCLOPRAMIDE;
ONDANSETRON;
OXALIPLATIN;
PALONOSETRON;
SEROTONIN 3 ANTAGONIST;
SEROTONIN ANTAGONIST;
STREPTOZOCIN;
UNINDEXED DRUG;
BREAST CANCER;
CHEMOTHERAPY INDUCED EMESIS;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONFERENCE PAPER;
DISEASE CONTROL;
DRUG CLASSIFICATION;
DRUG DOSE COMPARISON;
DRUG HALF LIFE;
DRUG RECEPTOR BINDING;
EVIDENCE BASED MEDICINE;
GENETIC POLYMORPHISM;
HUMAN;
MONOTHERAPY;
NAUSEA;
PRACTICE GUIDELINE;
RISK ASSESSMENT;
RISK REDUCTION;
SINGLE DRUG DOSE;
SOLID TUMOR;
|
|
EID: 39749084467
PISSN: 15446794
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (0)
|
